Quince Therapeutics, Inc. 8-K

What Happened
Quince Therapeutics, Inc. (QNCX) filed a Form 8-K on January 29, 2026 to furnish a press release dated January 29, 2026. The disclosure was made under Item 9.01 (Financial Statements and Exhibits) and the press release is included as an exhibit to the filing.

Key Details

• Filing date: January 29, 2026 (Form 8-K accession 0001193125-26-029524).
• Item reported: 9.01 (Financial Statements and Exhibits).
• Exhibit: Press release furnished with the 8-K (referenced as the exhibit to the filing).
• The 8-K does not report other Item changes (no other sections, such as Item 2.02 or Item 5.02, are indicated in this filing).

Why It Matters
An Item 9.01 filing means the company has publicly provided a press release that may contain material news — for example, updates on results, corporate actions, executive roles, or pipeline developments. Retail investors should read the attached press release (Exhibit) to see if it contains earnings, operational updates, management comments, or other information that could affect the stock. This 8-K itself only furnishes the press release; it does not independently amend prior SEC filings.